FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 405 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App September 18, 2021 EMA Recommends to Extend the Indications for Tislelizumab May 8, 2025 Long-Term Responders with No Evidence of Disease Have Better Survival to... May 16, 2022 Significant Activity, Clinically Meaningful Functional and Symptomatic Improvements Observed in Patients... June 20, 2024 Load more HOT NEWS Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis New on NCI’s Websites for March 2025 ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current... Presence of Tumour and Higher Levels of LAG3-positive T-cells in the...
